scholarly journals Screening mutations in miRNA196a2 and miRNA148a in Vietnamese breat cancer patients

2014 ◽  
Vol 17 (4) ◽  
pp. 49-64
Author(s):  
Thach Thi Ngoc Nguyen ◽  
Hai Thanh Hoang ◽  
Hue Thi Nguyen
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Dominant Frequency ◽  
Breast Cancer Patients ◽  
Common Cancer ◽  
Genotype Frequencies ◽  
Pcr Product ◽  
Breat Cancer ◽  
Melting Analysis ◽  
Larger Sample

Breast cancer, affecting women mostly, is the second common cancer in the world. Previous studies showed that miRNAs played a role in the regulation of signal transduction pathways in many different stages of cancer. The SNPs that occur on miRNA can have broad impact in cancer by many different ways. It was found that SNP rs11614913 C>T in miR-196a2 related to breast cancer risk in Asia. In addition, the association between SNP rs6977848 T> G in miR-148a and breast cancer have early proven on the Australian. In this study, a combination of Tetra-Arms-PCR and PCR product melting analysis,was used to screen for the presence of the allele of rs11614913 and rs6977848 in Vietnamese breast cancer patients. The results showed that the frequency of C and T allele ofrs11614913 were 58.96 % and 41.04 % respectively; the frequency of T and G allele of rs6977848 were 99 % and 1 %, respectively. Based on the genotype frequencies in the HapMap, rs11614913 is predicted to be associated with breast cancer while rs6977848 is probably not related to breast cancer in Vietnam due to a highly dominant frequency of only one type allele. However, there is still need for further research on a larger sample size to confirm the association between the two SNPs with breast cancer in Vietnam.

scholarly journals Spectrum of breast cancer patients: twin institutional study

2017 ◽  
Vol 4 (9) ◽  
pp. 3077 ◽  
Author(s):  
Prabhat B. Nichkaode ◽  
Aditya Parakh
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Urban Population ◽  
Disease Stage ◽  
Rural India ◽  
Breast Cancer Patients ◽  
Female Population ◽  
Receptor Status ◽  
Common Cancer ◽  
Study Results

Background: Breast cancer is emerging as one of the most common cancer occurring in urban female population of India. It has become the second most common cancer in rural India, after cancer of uterine cervix. One must understand the diversity of presentation of breast cancer patients in the rural and urban population. Author is a surgeon working in a hospital which caters health care to both, rural as well as urban population. The present study is meant to review the data of various types of presentation, of cancer breast in two Institutes in different states. We also would like to compare our data with a few major cancer centers in metropolitan cities. The aim of the study was to present a data of patients with breast cancer at two institutes.Methods: This is a retrospective observational study carried out at two different medical teaching Institutes, CCM Medical College, Kachandur, Durg, Chhattisgarh and other at NKP Salve Institute of Medical Sciences Nagpur, Maharashtra. Study was carried out from 2009 till 2016 and total of 167 patients were included in the study. Data like age, menstrual status, size of lump, stage of disease, grade of disease (Bloom Richardson Elliston Index) and ER, PR, HER/neu receptor status of tumor, presence or absence of metastasis, and follow up records related to outcome, are presented in this study. Results: Out of 167 patients included in the study, two patients were males, and were excluded from our study. It becomes a study of 165 patients. Average age of patients at presentation was between 35 to 65 years. Majority of patients belong to stage III a (bulky operable disease) or III b, (locally advanced breast cancer) Stage II, and stage IV -metastatic disease. No patient of stage I disease reported in the present study. Most common pathological type was infiltrating ductal carcinoma.Conclusions: Breast cancer has emerged as the commonest cancer in urban India, with second most common cancer in rural India. Majority of our patients present with advanced disease stage with numerous poor prognostic factors such as young age, larger tumor size, lymph node metastasis, high pathological grade and poor hormone receptor status. These factors are a reflection of poor health awareness for breast cancer, general indifference towards women’s health, poor financial resources, unavailability of multimodality treatment facilities.

scholarly journals Initial determination of the association between SNP rs3937033 on the D-LOOP mtDNA and breast cancer in Vietnam

2018 ◽  
Vol 1 (6) ◽  
pp. 40-48
Author(s):  
Hanh Thi Hong Duong ◽  
Thanh Thi Ngoc Nguyen ◽  
Hue Thi Nguyen
Keyword(s):  
Breast Cancer ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Coding Region ◽  
Genotype Frequencies ◽  
Potential Biomarker ◽  
D Loop ◽  
And Control ◽  
Larger Sample

Breast cancer (BC) is the most common cancer among women and accounts for the highest mortality rates in the developing countries, including Vietnam. D-loop, is a non-coding region in mitochondrialcircular DNA molecules, related to control the replication and transcription of mitochondrial genes. D-loop mutations cause the dysfunction of the respiratory chain, which contributes to the process of BC. SNP rs3937033 (T/C) on D-loop was reported to have the association with BC in Europe America population (OR [95%CI]= 1.98 [1.25–3.12], P=0.036), and Caucasian (OR[95%CI]= 21 [2.15–204.6], P=0.003). In this study, the High Resolution Melting (HRM) method is optimized for genotyping 100/100 cases/controls samples, then to determine the association between the disease and this SNP. TT, TC and CC genotype frequencies in patient group (36 %, 3 % and 61 %) and control group (23 %, 1 % and 76 %) were calculated based on the results of genotyping by optimal HRM method with the annealing temperature is 66 0C. Association analysis result showed that T allele increases the risk of breast cancer patients up to 1.41 times (OR [95% CI] = 1.41 [1.3-1.92], Pallele = 0.03). Therefore, SNP rs3937033 could be a potential biomarker for early BC diagnosis in Vietnamese. However, this research needs to be conducted with a larger sample size to reach the greater confidence.

scholarly journals LIPID PROFILE AND ITS SIGNIFICANCE IN BREAST CANCER

2020 ◽  
Vol 8 (10) ◽  
pp. 1241-1248
Author(s):  
Sharmin Arif ◽  
◽  
Fauzia Abdus Samad ◽  
Syed Abdus Samad ◽  
Asif Riaz Khan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lipid Profile ◽  
Cancer Patients ◽  
Morbidity And Mortality ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Control Groups ◽  
Common Cancer ◽  
And Control ◽  
The Relationship

Background: According to WHO, breast cancer is the most common cancer in the women worldwide, soearly diagnosis is the best way to reduce its morbidity and mortality. Among various risk factors, the relationship between serum lipid profile and breast cancer is still unclear. Therefore, this study was conducted to evaluate this relationship. Methodology: Prospective, descriptive observational study with a comparative study designconducted at Fauji Foundation Hospital, Rawalpindi between November 2018 to April 2019. Results: 140 patients were divided into two groups i.e. cases and controls. Both groups were equally sub divided based on menstrual status. Independent student t-test was applied for comparison between the groups. BMI was significantly higher in the study group as compared to control group (p=0.002). Serum TG and LDL levels were higher in breast cancer patients (p= 0.032 and p=0.07 respectively). Cholesterol level was not statistically different in any group (p= >0.05). Higher HDL levels were seen in pre-menopausal cases (p=0.004) but there was no statistical difference when studied across cases and control groups. Conclusion: As breast cancer is the most common tumor in females, so early diagnosis is the key to reduce its morbidity and mortality. In this study, higher BMI, TG and LDL levels were seen in breast cancer patients as compared to controls. So, it may be concluded that BMI and dyslipidemia have some role in the etiology of breast cancer.

Evaluation of Ile655Val HER2 polymorphism associated with cardiac toxicity following the administration of trastuzumab in women with breast cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 634-634
Author(s):  
Caroline Diorio ◽  
Julie Lemieux ◽  
Marc-Andre Cote ◽  
Louise Provencher ◽  
Corinne Nadeau-Larochelle ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Cardiac Toxicity ◽  
Statistical Significance ◽  
Metastatic Breast ◽  
Fisher Exact Test ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Genotype Frequencies

634 Background: Trastuzumab is well tolerated without major side effects except for cardiac toxicity. Although a number of clinical parameters have been associated with trastuzumab-associated cardiac toxicity (TACT), there is some indication that genetic variation of the HER2 gene may play a toxic role in a population of metastatic breast cancer patients. However, this finding needs confirmation and we looked at a population of non-metastatic breast cancer. This study aimed to evaluate the association between cardiac toxicity and HER2 [Ile655Val] polymorphism in non-metastatic breast cancer patients treated with trastuzumab. Methods: The Ile655Val HER2 polymorphism was assessed in 73 women using TaqMan technology. For this study, the genotyping was performed using DNA extracted from normal breast tissue located at more than 1 cm of any other lesions. Charts review was used to collect information on TACT which was defined as any decline in LVEF > 10 % from the baseline to < 55 % or a decline in LVEF > 5 % to < 50 % (lower limit of normal). The Fisher exact test was used to evaluate the association between cardiac toxicity and HER2 polymorphism. Results: No deviation from the Hardy-Weinberg equilibrium has been observed for the allele and genotype frequencies. The distribution of HER2 polymorphism was 3 Val/Val (4%), 18 Ile/Val (25%) and 52 Ile/Ile (71%). In this population, 19% (14/73) developed a cardiac toxicity. We found that 29% (6/21) of Ile/Val or Val/Val carriers compared to 15% (8/52) of Ile/Ile carriers showed TACT, but this association did not reach statistical significance (P = 0.21). Conclusions: HER2 Ile655Val polymorphism may be an efficient marker of TACT considering this tendency with this small cohort of patients. Larger sample is needed to strengthen this conclusion, since this result may influence on prescribing decision for adjuvant chemotherapy and anti-HER2 therapy in HER2 positive patients.

Association of CYP19A1 gene variants with differences in disease progression in breast cancer patients from different racial/ethnic backgrounds.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1558-1558
Author(s):  
Reina Villareal ◽  
Angela W. Meisner ◽  
Lina Aguirre ◽  
Vibhati Kulkarny ◽  
Vallabh Shah ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Disease Progression ◽  
Cancer Patients ◽  
Racial Differences ◽  
Cancer Progression ◽  
Allele Frequencies ◽  
Response To Treatment ◽  
Gene Variants ◽  
Breast Cancer Patients ◽  
Genotype Frequencies

1558 Background: Polymorphisms in the aromatase (CYP19A1) gene result in differences in the risk for breast cancer and response to treatment. We hypothesize that allele frequencies in the CYP19A1 gene vary according to race and may result in differences in progression of breast cancer among women from different racial backgrounds. The objectives of this study are: 1) to determine the allele/genotype frequencies in the CYP19A1 gene among women with breast cancer from different racial backgrounds, and, 2) to determine the association between disease progression and CYP19A1 gene variants. Methods: Clinical data and stored DNA from 327 patients participating in the Expanded Breast Cancer Registry (EBCR) program at the University of New Mexico were analyzed. These patients were followed-up for a period of 1 to 6 years. Comprehensive genotyping for CYP19A1 gene single nucleotide polymorphisms (SNPs) was performed using microarray (Illumina). Results: Data from 164 non-Hispanic white and 119 Hispanic women were analyzed. Four SNPs (rs1259269, rs17703883, rs16964211, rs28757101) were associated with differences in genotype/allele frequencies between the 2 racial groups. Furthermore, 3 SNPs (rs4646, rs17647478, and rs6493486) were associated with differences in disease progression. The rare allele (G) for the rs17647478 (G/T) is associated with poor progression compared those without the allele (41.7% vs. 17.1%, p=0.04). Similarly the minor (A) allele for the rs4646 (A/C) and the rs6493486 (A/G) is also associated with a greater chance of worsening disease (23.2% vs. 12.4%, p=0.02 and 23.4% vs. 12.4%, p=0.02, respectively). A significant percentage of women carrying the A allele for both rs4646 and rs6493486 and the T allele for the rs17647478 have more advanced disease at the time of presentation. None of the SNPs analyzed result in racial differences in breast cancer progression. Conclusions: Polymorphisms in the CYP19A1 gene influence overall disease progression in breast cancer patients but have no impact on the racial differences of disease behavior. Women carrying the risk alleles present at a more advanced stage and are also at greater risk of progression.

Sign in / Sign up

Export Citation Format

Share Document